Author:
Bristow Cynthia L.,Winston Ronald
Abstract
The abundant blood protein α1-proteinase inhibitor (α1PI, Αlpha-1, α1-antitrypsin, SerpinA1) is known to bind to the active site of granule-associated human leukocyte elastase (HLE-G). Less well known is that binding of α1PI to cell surface HLE (HLE-CS) induces lymphocyte locomotion mediated by members of the low density lipoprotein receptor family (LDL-RFMs) thereby facilitating low density lipoprotein (LDL) clearance. LDL and α1PI were previously shown to be in negative feedback regulation during transport and clearance of lipoproteins. Further examination herein of the influence of α1PI in lipoprotein regulation using data from a small randomized, double-blind clinical trial shows that treatment of HIV-1-infected individuals with α1PI plasma products lowered apolipoprotein and lipoprotein levels including LDL. Although promising, plasma-purified α1PI is limited in quantity and not a feasible treatment for the vast number of people who need treatment for lowering LDL levels. We sought to develop orally available small molecules to act as surrogates for α1PI. Small molecule β-lactams are highly characterized for their binding to the active site of HLE-G including crystallographic studies at 1.84 Å. Using high throughput screening (HLE-G inhibition, HLE-CS-induced cellular locomotion), we show here that a panel of β-lactams, including the LDL-lowering drug ezetimibe, have the capacity to act as surrogates for α1PI by binding to HLE-G and HLE-CS. Because β-lactams are antibiotics that also have the capacity to promote evolution of antibiotic resistant bacteria, we modified the β-lactam Alphataxin to prevent antibiotic activity. We demonstrate using the diet-induced obesity (DIO) mouse model that Alphataxin, a penam, is as effective in lowering LDL levels as FDA-approved ezetimibe, a monobactam. Non-antibiotic β-lactams provide a promising new therapeutic class of small molecules for lowering LDL levels.
Subject
Pharmacology (medical),Pharmacology
Reference53 articles.
1. Antileishmanial Activity of Ezetimibe: Inhibition of Sterol Biosynthesis, In Vitro Synergy with Azoles, and Efficacy in Experimental Cutaneous Leishmaniasis;Andrade-Neto;Antimicrob. Agents Chemother.,2016
2. Comparison of Properties of Membrane Bound versus Soluble Forms of Human Leukocytic Elastase and Cathepsin G;Bangalore;Biol. Chem. Hoppe-Seyler,1994
3. Kinetics of Association of Serine Proteinases with Native and Oxidized Alpha‐1‐Proteinase Inhibitor and Alpha‐1‐Antichymotrypsin;Beatty;J. Biol. Chem.,1980
4. Pharmacological Profile of the Substituted Beta-Lactam L-659,286: A Member of a New Class of Human PMN Elastase Inhibitors;Bonney;J. Cel. Biochem.,1989
5. Wnt Pathway Activation, Cell Migration, and Lipid Uptake Is Regulated by Low-Density Lipoprotein Receptor-Related Protein 5 in Human Macrophages;Borrell-Pagès;Eur. Heart J.,2011
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献